The FNIH has issued a request for applications (RFA) for the Accelerating Medicines Partnership® in Parkinson’s Disease and Related Disorders (AMP® PDRD). If you are a clinical investigator with established study cohorts in Parkinson’s disease, other alpha-synucleinopathies (including Lewy body dementia, multiple system atrophy, or REM sleep behavior disorder), or atypical parkinsonian syndromes, such as progressive supranuclear palsy, AMP PDRD invites you to apply. Investigators have the opportunity to perform biomarker analyses, fully funded by the AMP PDRD consortium, at no cost to the investigator.
_______